Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Class III antiarrhythmic

Updated · Methodology

Mechanism

Both dronedarone and domperidone prolong the QT interval. Dronedarone moderately prolongs the Bazett-corrected QT interval (QTc), by about 10 ms, because repolarisation lasts longer (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish domperidone SmPC explains that such combinations raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions, and lists dronedarone among the contraindicated class III antiarrhythmics (domperidone SmPC, AEMPS). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and drugs that markedly inhibit this enzyme may raise its plasma level (domperidone SmPC, AEMPS). Dronedarone is a moderate CYP3A4 inhibitor (dronedarone SmPC, EMA), but the documents do not say how much it raises domperidone levels.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dronedarone can cause proarrhythmic effects when taken with drugs that favour arrhythmias or with electrolyte disorders (dronedarone SmPC, European Medicines Agency, EMA). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS), and a slow heart rate is among the side effects of dronedarone (dronedarone SmPC, EMA).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names dronedarone among the class III antiarrhythmics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The dronedarone documents contraindicate it with drugs that can induce torsade de pointes and with class I and III antiarrhythmics. Their example lists do not name domperidone, but according to its own SmPC domperidone prolongs the QT interval and torsade de pointes has been reported with it (dronedarone SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA; domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Dronedarone is contraindicated in current or past heart failure, with a heart rate below 50 beats per minute and with a Bazett-corrected QT interval (QTc) of 500 ms or more (dronedarone SmPC, EMA). Monitor the electrocardiogram (ECG) during dronedarone treatment, stop dronedarone if the QTc reaches 500 ms, and correct any potassium or magnesium deficiency before and during treatment (dronedarone SmPC, EMA). If domperidone and dronedarone have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Dronedarone